pleural

K-975 is a highly selective, orally active TEAD inhibitor, effectively inhibiting protein-protein interactions between TEAD and YAP1/TAZ.

Ifebemtinib (BI-853520) is an orally active and potent inhibitor of adhesion plaque kinase (FAK) (IC50=1 nM) with anti-tumour activity that inhibits globule formation and in situ tumour growth in malignant pleural mesotheliomas, and may be useful for the study of breast and ovarian cancer.

Pemetrexed disodium heptahydrate (LY231514) is an antifolate that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinyl-adenosine 5'-monophosphate (GARMT) with K_i values of 1.3 nM, 7.2 nM, and 65 nM respectively. This inhibits the formation of precursor purine and pyrimidine nucleotides and cancer cell proliferation, making it suitable for research into pleural mesothelioma and non-small cell lung cancer (NSCLC).

Wollastonite is an industrial mineral comprised chemically of calcium, silicon, and oxygen. It has been determined to have low biopersistence in both in vivo and in vitro studies, which probably accounts for its relative lack of toxicity. There are no ple

1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (16:1 PE) is a phosphatidylethanolamine that can enhance the activities of PP2A and PTP1B in malignant pleural mesothelioma cells. Additionally, 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine induces apoptosis in NCI-H28 malignant pleural mesothelioma cells.

AHR-10037 is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic properties as well as a high therapeutic index and low gastric toxicity. AHR-10037 was comparable to indomethacin in suppressing acute (Evans blue-carrageenan pleural effusion) and chronic (adjuvant-induced arthritis) inflammation. Studies have shown that it is converted in vivo to a prodrug of cyclooxygenase inhibitors.

Pemetrexed tromethamine is a chemotherapy drug used for pleural mesothelioma and non-small cell lung cancer.

MYF-03-176 is an orally active TEAD1/3/4 inhibitor with IC₅₀ values of 47/32/71 nM, respectively. It also inhibits TEAD transcriptional activity and cell growth in NCI-H226 cells, exhibiting antitumour activity in malignant pleural mesothelioma (MPM) cells with defective Hippo signalling and in mouse xenograft models.

Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM).

Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.Anetumab can be used to synthesize the antibody-activated molecule coupling, Anetumab ravtansine.Anetumab can be used to study the treatment of metastatic pleural mesothelioma.